Illumina Inc. (NASDAQ: ILMN) announced changes to its board of directors, with three current members retiring and one new nomination ahead of the company's annual shareholder meeting.

Frances Arnold, Robert S. Epstein, and Gary S. Guthart will retire from the board in connection with the upcoming annual meeting. The board has nominated David P. King for election as a new director.

King previously served as executive chairman and CEO of Laboratory Corporation of America Holdings. He currently serves as director and chair of Privia Health and AmSurg Corporation, and as a director of Smith & Nephew. His recent board positions include ZimVie from 2022 to 2025 and VaxCare from 2021 to 2025.

Before joining LabCorp in 2001, King worked as a partner at Hogan & Hartson LLP, where he led the firm's healthcare fraud and abuse practice, representing healthcare companies in investigations and litigation.

"Dave brings operating experience, public company board leadership, and regulatory insight forged across the healthcare and life sciences landscape," said Scott Gottlieb, chair of the board.

The retiring directors helped guide the company through what Gottlieb described as a period of transformation. Arnold holds a PhD, Epstein is a medical doctor, and Guthart holds a PhD.

Illumina develops DNA sequencing and array-based technologies for research, clinical, and applied markets. The company's products are used in life sciences, oncology, reproductive health, agriculture, and other segments.